In the intramuscular immunomodulator segment, Astragalus polysaccharide oral solution veterinary grade API is formulated into an injectable solution at a working concentration of 0.15%–0.50% w/v (1.5–5.0 mg/mL) in Water for Injection buffered with phosphate to pH 5.5–6.5. The dry API is pre-dried at 40 °C for 12 h when storage relative humidity exceeds 60%, because residual moisture above 8% shifts the powder into a cohesive mass that extends dissolution time beyond 45 min in a 100 L stainless-steel mixing tank equipped with a bottom-entering magnetic stirrer. Dissolution is conducted at 25–35 °C under vacuum protection to limit oxidative browning; the resulting solution is clarified through a 0.45 µm polypropylene depth filter before terminal sterile filtration through a 0.22 µm PES membrane. Terminal autoclaving at 121 °C for 15 min is avoided on production lines where thermal exposure reduces the high-molecular-mass fraction and increases color intensity; aseptic filtration therefore remains the preferred route for heat-sensitive polysaccharide solutions. The sterile filtrate is filled into 100 mL Type II glass vials with bromobutyl rubber stoppers under Grade B/ISO 5 conditions. Sterility is controlled according to Ph. Eur. 2.6.1 or USP <71>, and bacterial endotoxins per Ph. Eur. 2.6.14 or USP <85>, with an acceptance limit calculated from the maximum dose volume; for a 1 mL dose, a limit of <0.5 EU/mL is commonly applied. Residual solvent compliance follows VICH GL18(R2) when ethanol precipitation is used during API extraction. The terminal product is a sterile injectable solution for swine and cattle, supplied in multi-dose vials for intramuscular administration. Operational limitations include incompatibility with oxidizing preservatives and the need to avoid prolonged exposure to stainless-steel surfaces at acidic pH below 4.0, which may induce iron-mediated discoloration.

What Changes When a 1:1000 Drinking-Water Dose Must Remain Clear for Six Hours?

Poultry drinking-water soluble powders require dissolution at 100–300 mg/L final drinking water; the API is blended with anhydrous dextrose or lactose carrier and 0.5% colloidal silicon dioxide to preserve flow. Production uses a 500 L double-cone tumble blender with intensifier bar; blend uniformity is verified by sampling 10 locations and analyzing polysaccharide content with a UV-Vis anthrone-sulfuric acid assay, with relative standard deviation <5% per ISO 6497:2002. Moisture must remain below 5.0%, and water activity is held at aw <0.35 before packaging into aluminium foil laminated sachets. In field water with residual chlorine 0.5–1.0 ppm, polysaccharide oxidation may reduce recovery by a measurable but formulation-dependent amount; published data for this specific configuration is limited, so producers should conduct on-site stability trials. Microbiological quality for non-sterile oral powder is assessed per Ph. Eur. 5.1.4 category 3B, with total aerobic microbial count ≤10³ CFU/g, yeast/mould ≤10² CFU/g, and absence of Salmonella per ISO 6579-1:2017. The terminal product type is a 100 g or 1 kg water-soluble powder sachet for broiler and layer drinking-water lines. The process limitation is that venturi dosing systems should not exceed 60 °C in recirculating water loops, because viscosity increases and may block nipple drinkers.

Compliance checklist matrix for Astragalus polysaccharide veterinary dosage forms

Dosage form	Standard / clause	Test method	Typical acceptance criterion
Injectable solution	Ph. Eur. 2.6.1 / USP <71>	Membrane filtration sterility	No growth after 14 days
Injectable solution	Ph. Eur. 2.6.14 / USP <85>	LAL kinetic chromogenic	Dose-calculated; commonly <0.5 EU/mL
Water-soluble powder	Ph. Eur. 5.1.4 category 3B	Total viable aerobic count	≤10³ CFU/g
Water-soluble powder	ISO 6579-1:2017	Salmonella detection	Absent in 25 g
Feed premix	ISO 6497:2002	Quartering sampling	Coefficient of variation <5%
Oral drench solution	Ph. Eur. 5.1.3	Preservative efficacy	3-log bacterial reduction at Day 14
Oral tablet	USP <905>	Content uniformity	Acceptance value ≤15
Oral granule	Ph. Eur. 2.2.32	Loss on drying	Moisture <4%

Feed-mill premix lines that incorporate a 1% spraying-grade microgranular premix use the API at an addition rate of 2–5 kg/ton complete feed, equivalent to 20–50 ppm polysaccharide in final rations for weaned pigs and breeding sows. The first dilution step combines the API with ground rice hulls or calcium carbonate in a 200 L paddle mixer for 20 min; the resulting premix is then metered by a loss-in-weight screw feeder into a horizontal ribbon mixer at the feed mill. Uniformity is checked with ISO 6497:2002 sampling, and the coefficient of variation on triplicate samples should remain <5%; use of a 1 mm sieve before blending removes agglomerates that cause carryover into clean batches. Because the polysaccharide is hygroscopic, the premix is packed immediately into 25 kg multi-wall paper bags with an inner polyethylene liner, and storage is specified below 25 °C and 60% RH. The terminal product is a medicated premix or feed supplement; if marketed as a zootechnical feed additive in the EU, the dossier falls under Regulation (EC) No 1831/2003, and feed hygiene requirements fall under Regulation (EC) No 183/2005. Heavy metals in the premix are controlled per ISO 6869:2000 for zinc and arsenic, with limits consistent with regional feed codes. Cross-contamination limitations require that the mixer and transfer lines be purged with 10 kg ground corn after the run; published data for batch-specific carryover below 0.5% of active ingredient is limited and should be validated on the actual line.Oral drench solutions delivered by syringe pump to neonatal calves use the API at 2%–4% w/v in a buffered vehicle containing sodium benzoate (0.1%) and potassium sorbate (0.08%) to preserve the non-sterile multi-dose pack. The solution is prepared in a 500 L jacketed stainless-steel vessel at 30–35 °C, then cooled to 15–20 °C before filling into 1 L HDPE bottles with tamper-evident caps. Because polysaccharide solutions are prone to foaming during transfer, the filling line uses a positive-displacement pump with 10 mm internal diameter tubing and a nozzle submerged below the liquid surface. The terminal product is an oral solution for calves, lambs, and pigs, administered via drench gun or mixed into milk replacer at 1–2 mL per 10 kg body weight. Microbiological quality is controlled per Ph. Eur. 5.1.4 category 3B, with total aerobic count ≤10² CFU/mL for oral liquids containing antimicrobial preservatives, and Escherichia coli absent per Ph. Eur. 2.6.13 or ISO 16649-2:2001. Preservative efficacy testing is conducted according to Ph. Eur. 5.1.3; the system must achieve a 3-log reduction for bacteria at Day 14. The operational limitation is that benzalkonium chloride should not be used as the sole preservative because interaction with anionic polysaccharide fractions can form insoluble complexes; if only benzalkonium chloride is available, a compatibility test with pH adjustment to 5.0–5.5 is required before scale-up.

If Astragalus Polysaccharide Is Added After Aluminum Hydroxide Antigen Adsorption, Low-Shear Blending Avoids Flocculation

Inactivated viral vaccine adjuvants containing the polysaccharide at 0.2%–1.0% w/v in the final aqueous antigen phase require strict order-of-addition control. The antigen is first adsorbed onto aluminum hydroxide gel at pH 6.3–7.2 for 2–4 h at 4 °C under magnetic stirring; the polysaccharide solution, prepared separately at 10% w/v in Water for Injection and filtered through a 0.22 µm PES membrane, is then added at 2–10% v/v. Mixing is performed with a low-shear turbine agitator at 50–100 rpm; high-shear rotor-stator homogenization above 3,000 rpm may destabilize the gel and increase mean particle size. The blend is held at 4 °C for 24 h before filling into 250 mL HDPE vaccine bottles. Sterility is verified per Ph. Eur. 2.6.1 or USDA 9 CFR 113.26 if relevant; endotoxin testing follows Ph. Eur. 2.6.14 or USP <85>. For veterinary biologics in the United States, serial release testing under 9 CFR Part 113 and pharmacovigilance under 9 CFR Part 116 apply; in the European Union, the product is controlled as a veterinary medicinal product under Directive 2001/82/EC as amended. The terminal product is an inactivated poultry or swine vaccine with Astragalus polysaccharide as co-adjuvant or immunostimulant. A limitation is that polysaccharide solutions stored above 10 °C for more than 72 h may show microbial growth if not preserved; aseptic handling and single-use aliquots are required. Published data for the exact adsorption isotherm of Astragalus polysaccharide onto aluminum oxyhydroxide in this formulation is limited; therefore each antigen type requires a dose-titration and zeta-potential check before pilot scale-up.Direct compression of the API into companion animal tablets begins with dry blending of an 80 mg per tablet dose (32% w/w of the core) with microcrystalline cellulose (30% w/w), lactose monohydrate (25% w/w), crospovidone (2% w/w), and magnesium stearate (1% w/w). Before compression, the blend is passed through a 0.8 mm screen and conditioned at 25 °C and 35% RH for 4 h; if room humidity exceeds 55% RH, the blend picks up moisture and sticks to the upper punch face. Compression on a rotary tablet press is run at 12–18 kN main compression force, producing 250 mg tablets with hardness 90–120 N, friability <0.8% per USP <1216>, and disintegration <15 min in 37 °C water per USP <701>. Content uniformity is tested per USP <905> with acceptance value ≤15. Coating with an aqueous HPMC film below 60 °C avoids surface tack; film-coated tablets are then packed into 60-count HDPE bottles with silica gel desiccant. The terminal product type is an oral tablet for dogs or cats as a non-prescription immune support supplement in jurisdictions that allow such claims. Stability of the polysaccharide in this matrix under ICH conditions 40 °C/75% RH for 6 months is commonly evaluated; published data for this specific configuration is limited, and the hygroscopic fraction can lower hardness over time if bottles are not induction-sealed. Heavy metal limits follow USP <2232> or Ph. Eur. 2.4.8, and microbial limits for non-sterile oral dosage forms follow Ph. Eur. 5.1.4.

Fluid-Bed Granulation Endpoints for Astragalus Polysaccharide Oral Granules in Calves

Oral granules destined for calf and foal oral administration are produced by top-spray fluid-bed granulation with the API at 15%–25% w/w in the dry granule, using a povidone or hydroxypropyl methylcellulose binder solution at 5% solids sprayed at 2.5–4.0 g/min/kg bed mass. Inlet air temperature is maintained at 50–60 °C, and product temperature at 28–34 °C; exceeding 65 °C inlet causes surface crusting and the formation of non-disintegrating aggregates. Granules are dried to moisture <4% and sieved through 1.0 mm and 0.25 mm screens; the target yield fraction between 0.25–1.0 mm is ≥85%. The terminal product is a 500 g or 1 kg oral granule jar for dosing by scoop or mixing into milk replacer. Compliance for non-sterile veterinary oral preparations follows Ph. Eur. 5.1.4 category 3B, and residual solvents from binder preparation are controlled under VICH GL18(R2). Uniformity of mass for single-dose granules is evaluated with Ph. Eur. 2.9.5; loss on drying is performed per Ph. Eur. 2.2.32 using 105 °C to constant mass. Operation limitations include avoiding direct contact with steam humidification systems because the polysaccharide transitions to a sticky gel layer on granule surfaces at moisture above 12%, causing aggregation in bulk containers. The fluid-bed process is not suitable for formulations containing heat-sensitive probiotics unless the polysaccharide is dry-blended after probiotic coating, not co-granulated.